Lotefort LS Ophthalmic Suspension contains Loteprednol etabonate 0.2% w/v, a corticosteroid indicated for the treatment of inflammatory conditions of the eye, including allergic conjunctivitis, postoperative inflammation, and anterior uveitis. Loteprednol etabonate is a corticosteroid with potent anti-inflammatory properties, designed to reduce ocular inflammation by inhibiting the release of inflammatory mediators and suppressing the immune response. The suspension formulation allows for effective topical delivery to the ocular tissues, ensuring rapid onset of action while minimizing systemic absorption. Lotefort LS is typically administered as one or two drops into the affected eye(s) four times daily or as directed by a healthcare professional. Caution is advised in patients with ocular infections, glaucoma, or a history of corticosteroid-induced intraocular pressure elevation. Prolonged use may increase the risk of cataract formation and secondary ocular infections; therefore, patients should be monitored regularly during therapy. Lotefort LS Ophthalmic Suspension should be used with care in pregnant or breastfeeding women, and its safety and efficacy in pediatric patients have not been fully established. Proper administration technique and adherence to prescribed dosing are essential to optimize therapeutic outcomes and minimize adverse effects.